Added to YB: 2025-02-24
Pitch date: 2025-02-21
TMDX [bearish]
TransMedics Group, Inc.
-76%
current return
Author Info
Scorpion Capital specializes in intensive, differentiated research which uncovers what investors have missed and Wall Street is paid to ignore. Sign up for the newsletter.
Company Info
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally.
Market Cap
$4.5B
Pitch Price
$72.04
Price Target
N/A
Dividend
N/A
EV/EBITDA
35.52
P/E
51.63
EV/Sales
7.99
Sector
Health Care Equipment and Supplies
Category
turnaround
TransMedics (TMDX): Layoffs, Hiring Freeze, and Competitive Pressure Signal Trouble
TMDX short: Alleged major layoffs (70-170) in Q4, hiring freeze. LinkedIn data shows collapsed hiring/job postings. Competitor OrganOx rapidly scaling, doubling headcount, suggesting market share erosion. Retail investors missing story, focusing on faulty flight data. No 8-K filed despite material changes.
Read full article (1 min)